Drug Profile
NBF 006
Alternative Names: NBF-006Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Nitto Biopharma
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Glutathione S-transferase pi expression inhibitors; Glutathione S-transferase pi inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 11 Oct 2023 Adverse events data from a phase I trial in Non-small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 11 Oct 2023 Adverse events data from a preclinical trial in Non-small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 11 Oct 2023 Pharmacodynamics data from a preclinical study in Non-small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)